

Corrections

In the article entitled, “Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer Progression” (Volume 178, pages 1350–1360, of the March 2011 issue of *The American Journal of Pathology*), the third author’s name was listed incorrectly. The correct name is Tian Huai Shen.

In the article entitled, “Abnormal Cell Properties and Down-Regulated FAK-Src Complex Signaling in B Lymphoblasts of Autistic Subjects” (Volume 179, pages 66–74 of the July 2011 issue), the current address of Hongen Wei was listed incorrectly. The current address of Dr. Wei is the Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

In the article entitled, “Spatiotemporal and Functional Behavior of Airway Dendritic Cells Visualized by Two-Photon Microscopy” (Volume 179, pages 603–609 of the August 2011 issue), the first author’s name was listed incorrectly. The correct name is Tibor Z. Veres.

In the article entitled, “Annexin 1 Released by Necrotic Human Glioblastoma Cells Stimulates Tumor Cell Growth

through the Formyl Peptide Receptor 1” (Volume 179, pages 1504–1512 of the September 2011 issue), the last author’s surname was listed incorrectly. The correct surname is Wang.

In the article entitled, “EMMPRIN Modulates Epithelial Barrier Function through a MMP-Mediated Occludin Cleavage Implications in Dry Eye Disease” (Volume 179, pages 1278–1286 of the September 2011 issue), the last author’s affiliation was listed incorrectly. The correct author affiliation is Fondation A de Rothschild,^{||} Paris, France; and INSERM UMR S 968,^{**} and the Institut de la Vision, Paris, France; Université Paris 7,⁺⁺ Diderot, Paris, France.

In the article entitled “Selective Stimulation of VEGFR2 Accelerates Progressive Renal Disease” (Volume 179, pages 155–166 of the July 2011 issue), part of panel J was inadvertently omitted in [Figure 2](#); the figure appears correctly online (HTML and PDF versions). The corrected [Figure 2](#) with legend appears on the following page.




Figure 2. Systemic overexpression of rAAV1-Flk-sel. **A:** Serum human VEGF-A concentrations in WT and eNOSKO mice treated with rAAV1-EV or rAAV1-Flk-sel at 3 months (before UNx). **B–E:** Representative PAS staining of glomerulus at 3 months from WT mice treated with rAAV1-EV (**B**) or with rAAV1-Flk-sel (**C**) and from eNOSKO mice treated with rAAV1-EV (**D**) or with rAAV1-Flk-sel (**E**). Flk-sel treatment did not change glomerular injury in either type of mouse at 3 months (**C** and **E**), compared with control EV treatment (**B** and **D**), whereas eNOSKO mice exhibited mild mesangial expansion with either treatment (**D** and **E**). Scale bar = 20 μ m. **F:** Western blot for renal VEGFR2 in whole kidneys of WT and eNOSKO mice treated with rAAV1-EV or rAAV1-Flk-sel 1 month after UNx. **G** and **H:** Quantitative analysis for VEGFR2 expression (VEGFR2/ β -actin ratio) (**G**) and phosphorylation (phosphorylated VEGFR2/total VEGFR2) (**H**). **I:** Western blot for VEGFR1 expression and phosphorylation. **J:** Western blot for phosphorylated Akt. **K:** Quantification of phosphorylated Akt. **L:** Representative photographs of eNOSKO mice treated with rAAV1-EV or rAAV1-Flk-sel after UNx. * $P < 0.01$; ** $P < 0.05$. Data are expressed as means \pm SD; $n = 10$ in each group.